Differential Crizotinib Efficacy among ROS1 Fusion Partners in ROS1-Positive Non-Small-Cell Lung Can - 华夏病理网手机站

Differential Crizotinib Efficacy among ROS1 Fusion Partners in ROS1-Positive Non-Small-Cell Lung Can

Moonshadow 2017-06-23

转载 213 0

From 2017 ASCO POSTER

上一篇：MET amplification(amp) is a major resistance mechanism to osimertinib-From 2017 ASCO POSTER

下一篇：BRAF Fusion in Clinically Advanced Non-small Cell Lung Cancer: An Emerging Target for anti-BRAF Ther

相关推荐

评论 (0)